Purpose
The aim of this study was to determine the volume of pancreas before and after sorafenib and TACE treatments in patients with advanced hepatocarcinoma without tumor progression. Our hypothesis was that only the pancreas of patients treated with sorafenib will decrease in size while those treated with TACE will maintain stable pancreatic volumes.
Methods and materials
Retrospective monocentric study including patients who recieved sorafenib and patients who underwent TACE procedures, with a 1 year follow-up.
Pancreatic volume was mesure before and after 1 year of initiated the systemic treatment or of the 1st TACE.
Consecutive areas of interest covering the pancreas were depicted in portal phase of CT studies. The addition of all areas was multiplied by the slice thickness to obtain pancreatic volume (figure 1).
14 patients were included in the sorafenib group and 9 in TACE group. Demographics and...
Results
There were statistically significant differences in pancreas volumetry in patients before and after long term sorafenib treatment (p=0'01). No differences were observed in the pancreatic volume of patients in TACE group (p= 0'56).
Conclusion
Sorafenib administration was mainly associated to a reduction of pancreatic volume during follow-up. Pancreatic volume remains stable in the TACE group.
The suspected mechanism in reduction of pancreatric volume in patients under sorafenib is the anti-angiogenic effect of the inhibited vacular endothelial growth factor causing a disturbance of microvasculation. Although the incidence of acute pancreatitis after TACE has been reported, we have not appreciated changes in pancreatic volumetry in our group.
Radiologists must be awared of changes in pancreatic volumetry to asses their clinical side...
Personal information and conflict of interest
E. Belmonte Castan; Barcelona/ES - Grant Recipient at BTG A. Darnell; Barcelona/ES - Speaker at Bayer - Grant Recipient at Bayer J. Rimola; Barcelona/ES - Speaker at Bayer - Grant Recipient at Bayer M. Reig; Barcelona/ES - Consultant at Bayer, BMS, Roche, Ipsen, AstraZeneca and Lilly - Grant Recipient at Bayer and Ipsen. - Speaker at Bayer, BMS, Gilead, and Lilly C. Ayuso; Barcelona/ES - Speaker at Bayer - Grant Recipient at Bayer V. Sapena; Barcelona/ES - nothing to disclose
References
Influence of Sorafenib and Bevacizumab on pancreatic volume - A monocentric CT based analysis.
Phillip V, Zahel T, Bärtl K, Rasch S, Ebert O, Schmid RM, Rummeny E, Algül H.
Pancreatology. 2016 Jul-Aug;16(4):621-4. doi: 10.1016/j.pan.2016.02.010. Epub 2016 Feb 27.
Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib.
Ganten MK, Schuessler M, Bruckner T, Ganten TM, Koschny R.
Oncology. 2015;89(2):88-94. doi: 10.1159/000377681. Epub 2015 Apr 2.
Organ Atrophy Induced by Sorafenib and Sunitinib - Quantitative Computed Tomography (CT) Evaluation of the Pancreas, Thyroid...